Keren Zhou, MD
Internal Medicine · Cleveland, OHNPI 1912326646
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,250 of the $7,287 with a category attached, or 72.0%. Xeris Pharmaceuticals, Inc. accounts for 75.1% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $5,837, more than ten times the $66 reported in 2019. Among internal medicine clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 37 payments — averaging $196.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Xeris Pharmaceuticals, Inc.$5K
- Corcept Therapeutics$722
- Medtronic$322
- Sanofi-aventis U.S. LLC$188
- Sequel Med Tech, LLC$166
- Vertex$120
- plus $296 from 8 others
Across 13 payments — averaging $9980.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Siemens Medical Solutions USA, Inc.$76K
- Biogen$51K
- Corcept Therapeutics$2K
What the payments were for
- Consulting fees$71310%
- Speaking & faculty fees$5,25072%
- Travel & lodging$270%
- Food & beverage$1,27818%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Xeris Pharmaceuticals, Inc. | 7 | $5,474 |
| Corcept Therapeutics | 2 | $722 |
| Medtronic(2 entities) | 2 | $322 |
| Sanofi-aventis U.S. LLC | 6 | $188 |
| Sequel Med Tech, LLC | 3 | $166 |
| Vertex | 1 | $120 |
| Dexcom, Inc. | 5 | $94 |
| Novo Nordisk | 5 | $87 |
| Insulet Corporation | 1 | $28 |
| Madrigal Pharmaceuticals | 1 | $20 |
| Mannkind Corporation | 1 | $20 |
| Advanced Accelerator Applications | 1 | $18 |
| Lilly USA, LLC | 1 | $16 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RECORLEV$5,350
- Korlym$713
- MINIMED 780G$286
- TWIIST$112
How this compares
$7,287 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 465 | $646,969 |
| RecorlevLevoketoconazole | 13 | $468,897 |
| OzempicSemaglutide | 247 | $356,819 |
| SigniforPasireotide Diaspartate | 12 | $236,974 |
| JardianceEmpagliflozin | 89 | $109,595 |
| Norditropin FlexproSomatropin | 24 | $85,028 |
| TrulicityDulaglutide | 58 | $71,619 |
| ForteoTeriparatide | 14 | $67,854 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 32 | $65,664 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 56 | $64,898 |
| JanuviaSitagliptin Phosphate | 26 | $39,073 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 20 | $35,289 |
| FarxigaDapagliflozin Propanediol | 26 | $33,769 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $24,780 |
| Humulin R U-500Insulin Regular, Human | 12 | $21,946 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog, Baqsimi | $16 | $806,278590 claims |
| Xeris Pharmaceuticals, Inc.Recorlev | $5,474 | $468,89713 claims |
| Novo NordiskOzempic, Xultophy 100-3.6, Fiasp, Novolog | $87 | $417,633309 claims |
| MerckJanuvia, Janumet | $12 | $47,98740 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Cleveland
- Cyrus HarrisCleveland$726K
- Marina MagreyCleveland$312K
- Joshua LonginowCleveland$241K
- Emad MansoorCleveland$219K
- Syed BukhariCleveland$165K
- Vadim KoshkinCleveland$159K
- Suresh Kumar BalasubramanianCleveland$148K
- Christine Tanaka-EspositoCleveland$123K
- Carla HarwellCleveland$75K
- Amr MohamedCleveland$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.